What To Expect From Roche In 2018

by Trefis Team
Roche Holdings
Rate   |   votes   |   Share

We expect Roche (NASDAQ:RHHBY) to post low-single-digit revenue growth in 2018, as its blockbuster oncology drug Rituxan faces biosimilar headwinds in Europe. Note that Rituxan sales were down 11% in Europe in 2017. Rituxan, Herceptin and Avastin are the top selling drug for Roche, accounting for over $19 billion in sales in 2017. For Roche, the Oncology segment will likely grow in low-single-digits led by a ramp up in sales of newer drugs, such as Tecentriq and Perjeta. We have created an interactive dashboard on how we expect 2018 to shape up for Roche. You can adjust forecasts and other estimates to see how changes would impact the company’s earnings. We forecast the company’s earnings to be around $2 per share in 2018.

Expect Roche’s Overall Sales In 2018 To Be $57B

Oncology Remains The Key Segment For Roche

Within Oncology, Tecentriq And Perjeta To Post Solid Growth While Rituxan, Herceptin, And Avastin Will Likely Post Low-Single-Digit Decline

Expect Earnings Per Share In 2018 To Be ~ $2

Our price estimate of $36 for Roche implies a premium of over 20% to the current market price.

What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

More Trefis Research

Like our charts? Explore example interactive dashboards and create your own

Rate   |   votes   |   Share


Name (Required)
Email (Required, but never displayed)
Be the first to comment!